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Nipah Virus in West Bengal, India
The cause of an outbreak of a febrile illness in West Bengal, India, which has affected at least 50 people since February 2007, has been
confirmed as due to Nipah virus (ProMED-mail archive number 20070508.1484).Originally the illness was thought to be due to an outbreak of a
new strain of dengue virus. To date (19 May 2007) three people in Nadia, West Bengal, are confirmed to have died from Nipah virus, by the
results of blood tests analysed by the National Institute of Virology in Pune, Maharashtra state. One of these three patients had been on a
business trip to Bangladesh in February, which may have been the origin of the outbreak. Reports from the beginning of May suggested there
were a further 30 febrile patients in Betai village and Krishnagar, awaiting the results of blood tests for Nipah virus (ProMED-mail archive
number 20070511.1514).
Nipha is a rare virus, which causes encephalitis and has a high mortality rate. It was first detected in Malaysia in 1999. Since then only two other
places are known to have been affected: Bangladesh and Bengal (West Bengal, India). Outbreaks of Nipah virus claimed the lives of 105 of the
265 people infected in Malaysia in 1999; 49 of 66 patients infected in Siliguri, Bengal in 2001; and 18 of 30 patients infected in Bangladesh in
April 2004. Symptoms include high temperature,muscle pain, nausea, and convulsions leading in some cases to coma and death in 48—72 hours.
The natural host of the virus is the fruit bat. Transmission requires close contact with infected tissues or body fluids and the virus is commonly
spread to humans and pigs via bat urine and saliva-contaminated fruit. In 1999, nearly a million pigs were slaughtered before the Malaysian
outbreak was brought under control. In the Siliguri outbreak in 2001, most patients were either hospital employees or visitors, suggesting the
possibility of human-to-human spread. However there have been no known cases of human-to-human infection, according to the World Health
Organization (WHO). Domestic cats and dogs have also been suspected as carriers.
Infection with Nipah virus has no cure, but the broad-spectrum antiviral ribavarin is being given in West Bengal to try to alleviate the symptoms
of nausea, vomiting, and convulsion. This drug was widely used for the cases of Nipah encephalitis in Malaysia in 1999, but there is little
evidence to support its use.
Rift Valley Fever in East Africa
Burundi: Reports on 10 May 2007 announced that one person has died from Rift Valley Fever (RVF) in Muyinga Province, North-East Burundi
(ProMED-mail archive number 20070519.1592). Up to 200 more people may be affected by the disease. This is the first report of RVF cases in
Burundi and represents a significant extension westwards of the RVF outbreak in East Africa. The infected patients are reported to have eaten
meat from animals that came from Tanzania.
United Republic of Tanzania: Between 13 January and 3 May 2007, there was a total of 264 cases of RVF reported in Tanzania. These included
109 deaths, which produces a case—fatality ratio of 41%. Only severe cases of RVF were detected through surveillance (as described below) and
154 of the 264 cases (60%) were laboratory confirmed http://www.who.int/csr/don/2007_05_09/en/index.html. Detailed information about
RVF in the Dodoma region of Tanzania, where the number of new cases seems to be falling, is available on ProMED-mail (ProMED-mail archive
number 20070516.1557).
As explained by the WHO disease outbreak news cited above, the surveillance of RVF, organized through the Integrated Disease Surveillance
and Response program, has been in place in Tanzania for several years. To investigate this outbreak, a WHO team from the Department of
Epidemic and Pandemic Alert and Response and the Regional Office for Africa has been assisting theWHO Country Office. Other national bodies
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have been working on the emergency response plan, including the early warning system, active case detection, case management and social
mobilization. A national investigation team conducted several field visits in the affected region to help with enhancement of surveillance, in-
depth case investigations and active surveillance activities. Among other activities, the team provided training in patient care for clinical staff
and in safe sample collection and shipment for laboratory staff.
Kenya: Between 30 November 2006 and 12 March 2007, 684 cases including 155 deaths of RVF were reported in Kenya (case—fatality ratio = 23%).
Of the 684 reported cases, 234 (34%) were laboratory confirmed.
Somalia: Between 19 December 2006 and 20 February 2007, a total of 114 cases including 51 deaths of RVF (case—fatality ratio = 45%) were
reported in Somalia. Only three were laboratory confirmed. During the outbreak response, the difficult security situation has continuously
hampered surveillance and control activities in the affected areas.
Extensively Drug-Resistant Tuberculosis (XDR TB): Air Travel Exposure
Aman who is infected with extensively drug-resistant tuberculosis (XDR TB) was on two commercial trans-Atlantic flights, Air France flight 385,
which left Atlanta for Paris on 12 May 2007, and Czech Air flight 104, which arrived in Montreal from Prague on 24 May 2007 (ProMED-mail
archive number 20070529.1738). As of the date of this writing (30 May 2007), it is not known in what countries the exposed individuals on the
flights reside.
The U.S. CDC is recommending the following for passengers and crew onboard these two flights:
Passengers seated in the same row as the index patient and those seated in the 2 rows ahead and the 2 rows behind, as well as the cabin crew
members working in the same cabin should be evaluated for TB infection. This includes initial evaluation and testing with follow up 8—10 weeks
later for re-evaluation.
After flying into Montreal, the man re-entered the U.S. by car. He was contacted by CDC officials in New York, and voluntarily reported to a
testing center, where he was found to have XDR-TB and ordered into isolation, according to Marty Cetron, director of the CDC’s division of
global migration.
The CDC flew the man to Atlanta where he had said he preferred to undergo treatment using a governmental (non-commercial) aircraft.
As noted in the Interim Recommendations for the Surveillance of Drug Resistance in Tuberculosis, published by the World Health Organization
in May 2007 (available at http://www.who.int/tb/publications/2007/who_htm_tb_2007_385.pdf), the World Health Organization convened
an Emergency Global Task Force on XDR TB in October 2006 (publication available at http://whqlibdoc.who.int/hq/2007/WHO_HTM_TB_
2007.375_eng.pdf). As a result, the revised definition of XDR TB is the following:
Isolateswith at least resistance to isoniazid and rifampicin (rifampin) and further resistance to a fluoroquinolone and one second line injectable
agent (amikacin, kanamycin, or the polypeptide capreomycin).
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